Navigation Links
PTC Therapeutics Awarded $1.6 Million FDA Orphan Drug Grant to Support an Ongoing Phase 3 Study in Cystic Fibrosis
Date:9/21/2010

SOUTH PLAINFIELD, N.J., Sept. 21 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced a grant award of approximately $1.6 million from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OPD) to support an ongoing Phase 3 study of ataluren in patients with nonsense mutation cystic fibrosis (nmCF).  The goal of the FDA's OPD grant program is to support the clinical development of products for use in rare diseases or conditions where no current therapy exists or where the proposed product will be superior to the existing therapy.

(Logo: http://photos.prnewswire.com/prnh/20010919/PTCLOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO)

"We are pleased to receive this grant from the FDA to support our ongoing development of ataluren for the treatment of nonsense mutation cystic fibrosis," stated Stuart W. Peltz, Ph.D., President and Chief Executive Officer of PTC Therapeutics.  "In addition to recognizing the potential of ataluren, this grant reflects PTC's long-standing commitment to developing new treatments for patients with rare genetic disorders that severely impact survival and quality of life."

The Phase 3 trial will enroll approximately 200 patients at research centers in North America, Europe and Israel.  The primary goal of the study is to evaluate whether ataluren can improve lung function as measured by forced expiratory volume (FEV1).  Other outcome measures will evaluate whether ataluren can decrease lung infections, reduce the frequency of cough and improve patient-reported quality of life.  Patients are randomized to receive either ataluren (40 mg/kg) or placebo daily for 48 weeks.  Study candidates include patients who are at least six years of age and have CF due to a nonsense mutation.

Patients with CF lack adequate levels of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, a chloride channel necessary for norm
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
2. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
3. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
4. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
5. Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer
6. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
7. CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
8. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
9. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
10. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
11. Arno Therapeutics Announces Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 22, 2014   BioTE Medical , a ... bio-identical hormone pellets, today announced the addition of ... company.   Dr. Rouzier is joining the BioTE Medical ... Dr. Rouzier was residency trained in Family ... a board certified emergency physician still practicing at ...
(Date:7/22/2014)... Rice Lake Weighing Systems ... NCSL International Workshop and Symposium July 28-31 in ... pressure instrumentation, OIML M1 weights, precision lab weights, ... sets, Essential Weights™. , NCSL International was formed ... solving the common problems faced by measurement and ...
(Date:7/22/2014)... 22, 2014  Neogen Corporation (NASDAQ: NEOG ... year, which ended May 31, increased 19% from the ... $28,158,000, compared to the prior year,s $27,190,000. Adjusted for ... per share in the current year were $0.76, compared ... income for the 2014 fiscal year established new all-time ...
(Date:7/22/2014)... and SHENZHEN, China ... Solutions Co., LTD, (BGI Tech), a subsidiary of ... the global launch of a new human whole ... platform. This newly offered service includes in-depth bioinformatics ... reduced prices until December 31, 2014. ...
Breaking Biology Technology:Dr. Neal Rouzier Joins BioTE Medical 2Dr. Neal Rouzier Joins BioTE Medical 3Rice Lake Weighing Systems Showcases Metrology Solutions for the 2014 NCSL International Workshop & Symposium 2Neogen reports 19% increase in annual revenues 2Neogen reports 19% increase in annual revenues 3Neogen reports 19% increase in annual revenues 4Neogen reports 19% increase in annual revenues 5Neogen reports 19% increase in annual revenues 6Neogen reports 19% increase in annual revenues 7Neogen reports 19% increase in annual revenues 8BGI Tech Launches Human Whole Exome Sequencing Service on Complete Genomics' Advanced Platform 2BGI Tech Launches Human Whole Exome Sequencing Service on Complete Genomics' Advanced Platform 3
... MIGENIX Inc. (the,"Company" or "MIGENIX") (TSX: MGI; ... infectious diseases, reports financial results for the ... a corporate update on its programs,and other ... Omiganan 1% gel (Omigard(TM)/CPI-226/MX-226; topical cationic ...
... decades-old drug to beat atherosclerotic plaques in research conducted ... , The scientists have found that drug-laced nanoparticles plus ... vessels that feed arterial plaques. Their results suggest that ... their growth, which could shrink or stabilize plaques. Although ...
... safe supply of drinking water for regions of the ... is rife. Writing in the International Journal of ... nanotubes could replace conventional materials in water-purification systems. , ... water will continue to grow as major global problems. ...
Cached Biology Technology:MIGENIX Reports First Quarter Fiscal 2009 Financial Results 2MIGENIX Reports First Quarter Fiscal 2009 Financial Results 3MIGENIX Reports First Quarter Fiscal 2009 Financial Results 4MIGENIX Reports First Quarter Fiscal 2009 Financial Results 5MIGENIX Reports First Quarter Fiscal 2009 Financial Results 6MIGENIX Reports First Quarter Fiscal 2009 Financial Results 7MIGENIX Reports First Quarter Fiscal 2009 Financial Results 8MIGENIX Reports First Quarter Fiscal 2009 Financial Results 9MIGENIX Reports First Quarter Fiscal 2009 Financial Results 10MIGENIX Reports First Quarter Fiscal 2009 Financial Results 11Old and new therapies combine to tackle atherosclerosis 2Old and new therapies combine to tackle atherosclerosis 3Water purification down the nanotubes 2
(Date:7/22/2014)... recent scientific discovery showed that mutations in prickle ... brain disorder characterized by repeated seizures over time. ... was unknown. , A new University of Iowa ... Proceedings of the National Academy of Sciences , ... epilepsy. UI researchers have identified the basic cellular ...
(Date:7/22/2014)... The Carlton Complex fires started on July 14, 2014, by ... Valley. The Carlton Complex consists of four fires: Stokes Fire, ... The Stokes and Gold Hikes fires are now one larger ... the area burning is currently over 243,000 acres in size. ... to the high fire danger. Public and firefighter safety is ...
(Date:7/22/2014)... known as the ,1000 Bull Genomes Project, aims to ... cattle while also improving animal health and welfare. Results ... the whole genomes of 234 individual bulls whose direct ... reported in the journal Nature Genetics . , ... information to reduce or eliminate hereditary diseases and to ...
Breaking Biology News(10 mins):UI study finds potential genetic link between epilepsy and neurodegenerative disorders 2Whole-genome sequencing of bulls in key beef and dairy breeds 2
... fossil tracks belonging to large, carnivorous dinosaurs have been ... Monash University and the Museum of Victoria (both in ... large dinosaurs were living in a polar environment during ... Antarctica and close to the South Pole. The ...
... triggered after specific engagement of foreign peptides (antigens) ... Cellular signaling pathways are responsible for the activation ... in T cells, which constitute a subgroup of ... in response to antigen stimulation. Malt1 is part ...
... team of Australian and Israeli researchers has discovered what ... event on Earth., An ancient light-sensitive gene has been ... for Coral Reef Studies (CoECRS) that appears to act ... corals across a third of a million square kilometres ...
Cached Biology News:Emory paleontologist reports discovery of carnivorous dinosaur tracks in Australia 2Key found to moonlight romance 2Key found to moonlight romance 3
... is an evolutionarily conserved form of cell ... The central component of this process ... caspases. These enzymes participate in a ... response to pro-apoptotic signals and result in ...
... DNA Visualizer Extraction Kit is manufactured for ... DNA damage byexposure to UV light. The ... is often used for DNA-cloning work. The ... bromide and exposure of UV light damages ...
... TargeTron(TM) Gene Knockout System provides optimized reagents ... disruption of bacterial genes by insertion of ... retrohoming ability of group II introns and ... the TargeTron group II intron for specific ...
Mouse monoclonal antibody raised against a partial recombinant VRK2. NCBI Entrez Gene ID = VRK2...
Biology Products: